In Moderna's COVID-19 vaccine trial, all but 11 of the 196 participants who contracted the virus were in the placebo group, good for a 94 percent efficacy rate. But perhaps even more crucially, none of the people who received the vaccine developed a severe infection, the company said. There were 30 severe cases in the trial — including one death — but they all occurred in the placebo group.
Experts have previously highlighted the importance of separating out worst the cases. Back in September, Drs. Peter Doshi and Eric Topol, in an op-ed for The New York Times, expressed concern that companies developing vaccines, including Moderna and Pfizer, which are on track to receive emergency approval from the Food and Drug Administration in the coming weeks, wouldn't specify the severity of the infections in their trial. But Moderna did just that Monday (Pfizer has also provided data on the matter), and the news is encouraging.
Back in September, we wrote about the need to show severe #COVID19 cases were prevented by a vaccinehttps://t.co/f5jvcdTCx2
Today we know that. Of @moderna_tx final efficacy all 30 severe cases were in the placebo group. pic.twitter.com/Pl1910I5nT
— Eric Topol (@EricTopol) November 30, 2020
More stories from theweek.com
Americans are choosing death over deprivation
Our parents warned us the internet would break our brains. It broke theirs instead.
Obama tells Stephen Colbert he messed up by not giving Dolly Parton the Presidential Medal of Freedom